Elinzanetant for the treatment of vasomotor symptoms associated with menopause
About The Study: In two pivotal phase 3 clinical trials, elinzanetant, a selective neurokinin-1,3 receptor antagonist, demonstrated statistically significant reductions in vasomotor...